any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

The following amendments are made with respect to the amended claims annexed to the International Preliminary Examination Report.

Please cancel claims 1-24 without prejudice or disclaimer.

Please add the following claims:

--25. (new) A composition for delivery of superoxide dismutase (SOD) to neuronal cells, comprising SOD linked by a cleavable linker to a neuronal cell targeting component, wherein said neuronal cell targeting component comprises a first domain that binds to a neuronal cell and a second domain that translocates the SOD of the composition into the neuronal cell.

a'

26. (new) The composition of claim 25 for delivery of SOD to mitochondria of neuronal cells wherein the SOD comprises a sequence targeting the SOD to mitochondria in the neuronal cell.

27. (new) The composition of claim 26 wherein the SOD is a hybrid of Mn-SOD and a sequence targeting the hybrid to mitochondria.

28. (new) The composition of claim 26 wherein the mitochondria targeting sequence is derived from human Mn-SOD.

29. (new) The composition of claim 25 wherein the SOD is bacterial SOD or is derived therefrom.

30. (new) The composition of claim 25 wherein the first domain is selected from the group consisting of

(a) neuronal cell binding domains of clostridial toxins; and

(b) fragments, variants and derivatives of the domains in (a) that substantially retain the neuronal cell binding activity of the domains of (a).

31. (new) The composition of claim 30 wherein the second domain is selected from the group consisting of

(a) domains of clostridial neurotoxins that translocate polypeptide sequences into cells; and

(b) fragments, variants and derivatives of the domains of (a) that substantially retain the translocating activity of the domains of (a).

32. (new) The composition of claim 25 wherein the linker is a disulphide bridge.

33. (new) A pharmaceutical composition for treatment of oxidative damage to neuronal cells comprising the composition of claim 25 and a pharmaceutically acceptable carrier.

34. (new) A method of delivering SOD to a neuronal cell comprising administering to a mammal an effective amount of the composition of claim 33.

35. (new) The method of claim 34 comprising injecting the composition.

36. (new) A composition for delivery of a therapeutic agent to neuronal cells, comprising the therapeutic agent linked by a cleavable linker to a neuronal cell targeting component, wherein said neuronal cell targeting component comprises a first domain that binds to a neuronal cell and a second domain that translocates the therapeutic agent of the composition into the neuronal cell.

37. (new) A polypeptide comprising a bacterial SOD or derivative thereof and a sequence for targeting the polypeptide to a human mitochondria.

38. (new) The polypeptide of claim 37 wherein the SOD is from *Bacillus*.

39. (new) The polypeptide of claim 37 which is a fusion protein.

40. (new) A nucleotide encoding the polypeptide of claim 37.

41. (new) A cell comprising the nucleotide sequence of claim 40.

42. (new) The composition of claim 25 wherein the cleavable linker is a disulphide bridge between first and second cysteine residues, wherein said first cysteine residue is on the SOD and said second cysteine residue is on the neuronal cell targeting component.

43. (new) The composition of claim 25 wherein the cleavable linker is a site for a protease found in neuronal cells.